Eteplirsen for the treatment of Duchenne muscular dystrophy

Annals of Neurology

Volumn 74, Issue 5, 2013, Pages 637-647

  Mendell, Jerry R ^a   Rodino Klapac, Louise R ^a   Sahenk, Zarife ^a   Roush, Kandice ^a   Bird, Loren ^a   Lowes, Linda P ^a   Alfano, Lindsay ^a   Gomez, Ann Maria ^a   Lewis, Sarah ^a   Kota, Janaiah ^a   Malik, Vinod ^a   Shontz, Kim ^a   Walker, Christopher M ^a   Flanigan, Kevin M ^a   Corridore, Marco ^b   Kean, John R ^a,b   Allen, Hugh D ^a   Shilling, Chris ^a   Melia, Kathleen R ^c   Sazani, Peter ^c   Saoud, Jay B ^c   Kaye, Edward M ^c   more..

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; DYSTROPHIN; ETEPLIRSEN; NEURONAL NITRIC OXIDE SYNTHASE; PLACEBO; PREDNISONE; SARCOGLYCAN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DUCHENNE MUSCULAR DYSTROPHY; EXON; FEMALE; GENE DELETION; HUMAN; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOLEMMA; SCHOOL CHILD; TREATMENT DURATION; WALKING SPEED;

EID: 84890805770     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23982     Document Type: Article

References (33)

1. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012; 71: 304-313.
2. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995; 74: S70-S92.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
4. Kohler M, Clarenbach CF, Böni L, et al. Quality of life, physical disability and respiratory impairment in Duchenne muscular dystrophy. Am J Respir Crit Care Med 2005; 172: 1032-1036.
5. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol 2012; 31: 121-125.
6. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677-2686.
7. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-928.
8. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-1522.
9. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
10. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-299.
11. Muntoni F, Torelli S, Ferlini A,. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2: 731-740.
12. Bushby KM, GardnerMedwin D,. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993; 240: 98104.
13. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798-810.
14. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy. N Engl J Med 2010; 363: 1429-1437.
15. Nguyen TM, Morris GE,. Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet 1993; 52: 1057-1066.
16. Arechavala-Gomeza V, Kinali M, Feng L, et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol 2010; 36: 265-274.
17. Klein CJ, Coovert DD, Bulman DE, et al. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992; 50: 950-959.
18. Winnard AV, Mendell JR, Prior TW, et al. Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet 1995; 56: 158-166.
19. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010; 41: 500-510.
20. Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011; 77: 250-256.
21. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010; 42: 966-974.
22. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in severe dystrophinopathy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013; May 14. [Epub ahead of print].
23. McDonald CM, Henricson, EK, Abresch, RT, et al. The 6-minute walk test and other endpoints in nonsense-mutation-mediated dystrophinopathy: longitudinal natural history observations in a multicenter study. Muscle Nerve 2013 May 16. [Epub ahead of print].
24. Strober JB,. Therapeutics in Duchenne muscular dystrophy. NeuroRx 2006; 3: 225-234.
25. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 456-473.
26. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903; erratum 1258.
27. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late onset Pompe's disease. N Engl J Med 2010; 362: 1396-1406.
28. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
29. Ahmad A, Brinson M, Hodges BL, et al. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet 2000; 9: 2507-2515.
30. Hoffman EP, Bronson A, Levin AA, et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle: progress in exon skipping and stop codon read through. Am J Pathol 2011; 179: 12-22.
31. Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587-1592.
32. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009; 65: 667-676.
33. Aartsma-Rus A, Janson AA, Kaman WE, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74: 83-92.